Data from: Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses

Caster O, Edwards IR

Date Published: October 16, 2015

DOI: http://dx.doi.org/10.5061/dryad.fh2nt

 

Files in this package

Content in the Dryad Digital Repository is offered "as is." By downloading files, you agree to the Dryad Terms of Service. To the extent possible under law, the authors have waived all copyright and related or neighboring rights to this data. CC0 (opens a new window) Open Data (opens a new window)

Title Sampled values for all probability variables of the benefit-risk assessment
Description The sampled values are based on probabilistic modelling of data from published clinical trials and from individual case safety reports contained in VigiBase, the WHO international database of suspected adverse drug reactions. The first two columns are used to determine what scenario of the assessment that is considered: the first column indicates the type of distribution over the derived risk intervals for the serious adverse effects, and the second column indicates the proportion of the sampled risk values that is attributed to the background. Each of the following columns belongs to one of the probability variables for one of the three considered treatment alternatives. Variables are listed in the order obtained when traversing the decision tree in Figure 3 top to bottom, starting from the leftmost level. There are 10,000 rows for each scenario. Abbreviations: HDMP=high-dose methylprednisolone, LDMP=low-dose methylprednisolone, NT=no treatment.
Download probabilities.csv (358.6 Mb)
Details View File Details
Title Sampled values for all utility variables of the benefit-risk assessment
Description These data have been generated by probabilistic modelling driven by qualitative relations specified between the considered clinical outcomes of the benefit-risk assessment. The first two columns are used to determine what scenario of the assessment that is considered: the first column indicates the severity of the relapse as measured by the patient's starting EDSS value, and the second column indicates the so called minimum utility difference between lethal and non-lethal outcomes. Each of the following columns belongs to the utility variable corresponding to one of the considered clinical outcomes. Variables are listed in the order obtained when viewing all branches of the decision tree in Figure 3 top to bottom. There are 10,000 rows for each scenario.
Download utilities.csv (434.2 Mb)
Details View File Details
Title Resulting samples for the expected utility of the three alternatives
Description The data displayed in this file are the resulting samples for the expected utility of the three considered treatment alternatives in all considered scenarios. They have been obtained by combining the data displayed in the two files 'Sampled values for all probability variables of the benefit-risk assessment' and 'Sampled values for all utility variables of the benefit-risk assessment', using the decision tree depicted in Figure 3 and the formulae given in Figure 1. The first four columns are used to determine what scenario of the assessment that is considered: the first column indicates the type of distribution over the derived risk intervals for the serious adverse effects; the second column indicates the proportion of the sampled risk values that is attributed to the background; the third column indicates the severity of the relapse as measured by the patient's starting EDSS value; and the fourth column indicates the so called minimum utility difference between lethal and non-lethal outcomes. The fifth, sixth, and seventh columns then show the computed expected utility values for high-dose methylprednisolone (HDMP), low-dose methylprednisolone (LDMP), and no treatment (NT), respectively. There are 10,000 rows for each scenario.
Download expected_utilities.csv (660.8 Mb)
Details View File Details
Title Resulting preference rates for the three alternatives
Description The data in this file has been computed directly from the raw data in the file 'Resulting samples for the expected utility of the three alternatives'. This file contains the same scenarios as that file, discernible from the the first four columns, but shows only a single value for each treatment alternative in each scenario. This value, the preference rate, is the fraction of all 10,000 sampling iterations for a given scenario in which the indicated alternative was the preferred one, i.e. had the highest expected utility. Preference rates for high-dose methylprednisolone (HDMP), low-dose methylprednisolone (LDMP), and no treatment (NT) are shown in columns 5-7, respectively. Figures 10 and 11 have been generated based on precisely this data.
Download preference_rates.csv (44.00 Kb)
Details View File Details

When using this data, please cite the original publication:

Caster O, Edwards IR (2015) Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurology 15: 206. http://dx.doi.org/10.1186/s12883-015-0450-x

Additionally, please cite the Dryad data package:

Caster O, Edwards IR (2015) Data from: Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. Dryad Digital Repository. http://dx.doi.org/10.5061/dryad.fh2nt
Cite | Share
Download the data package citation in the following formats:
   RIS (compatible with EndNote, Reference Manager, ProCite, RefWorks)
   BibTex (compatible with BibDesk, LaTeX)

Submissions have been temporarily disabled.

Search for data

Be part of Dryad

We encourage organizations to: